This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cardiac Myosin Activation With Omecamtiv Mecarbil in Systolic Heart Failure

Tuesday, November 17, 2020

Submitted by


Source Name: The New England Journal of Medicine


John R. Teerlink, Rafael Diaz, G. Michael Felker, John J.V. McMurray, Marco Metra, Scott D. Solomon, Kirkwood F. Adams, Inder Anand, Alexandra Arias-Mendoza, Tor Biering-Sørensen, Michael Böhm, Diana Bonderman, John G.F. Cleland, Ramon Corbalan, Maria G. Crespo-Leiro, Ulf Dahlström, Luis E. Echeverria, James C. Fang, Gerasimos Filippatos, Cândida Fonseca, Eva Goncalvesova, Assen R. Goudev, Jonathan G. Howlett, David E. Lanfear, Jing Li, Mayanna Lund, Peter Macdonald, Viacheslav Mareev, Shin-ichi Momomura, Eileen O’Meara, Alexander Parkhomenko, Piotr Ponikowski, Felix J.A. Ramires, Pranas Serpytis, Karen Sliwa, , Jindrich Spinar, Thomas M. Suter, Janos Tomcsanyi, Hans Vandekerckhove, Dragos Vinereanu, Adriaan A. Voors, Mehmet B. Yilmaz, Faiez Zannad, Lucie Sharpsten, Jason C. Legg, Claire Varin, Narimon Honarpour, Siddique A. Abbasi, Fady I. Malik, Christopher E. Kurtz for the GALACTIC-HF Investigators

A latge RCT of the first myosin inhibitor in severe chronic heart failure: somewhat difficult to interpret results, as deaths were slightly higher in the intervention group while there was no 'significant' benefit in cardiovascular deaths. The authors discuss the possibility of benefit in lower ejection fractions and proceed to discuss and present subgroups in an effort to glean some granularity in indications for omecamtiv mecarbil.

Add comment

Log in or register to post comments